KR20240155291A - 루푸스 신염 치료를 위한 입타코판의 용도 - Google Patents

루푸스 신염 치료를 위한 입타코판의 용도 Download PDF

Info

Publication number
KR20240155291A
KR20240155291A KR1020247031773A KR20247031773A KR20240155291A KR 20240155291 A KR20240155291 A KR 20240155291A KR 1020247031773 A KR1020247031773 A KR 1020247031773A KR 20247031773 A KR20247031773 A KR 20247031773A KR 20240155291 A KR20240155291 A KR 20240155291A
Authority
KR
South Korea
Prior art keywords
iptacopan
subject
dose
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247031773A
Other languages
English (en)
Korean (ko)
Inventor
야니나 리니크
마티아스 마이어
니콜라스 베프프
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20240155291A publication Critical patent/KR20240155291A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247031773A 2022-03-04 2023-03-03 루푸스 신염 치료를 위한 입타코판의 용도 Pending KR20240155291A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316623P 2022-03-04 2022-03-04
US63/316,623 2022-03-04
PCT/IB2023/052010 WO2023166487A1 (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
KR20240155291A true KR20240155291A (ko) 2024-10-28

Family

ID=85704041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247031773A Pending KR20240155291A (ko) 2022-03-04 2023-03-03 루푸스 신염 치료를 위한 입타코판의 용도

Country Status (10)

Country Link
US (1) US20250195492A1 (https=)
EP (1) EP4486343A1 (https=)
JP (1) JP2025507830A (https=)
KR (1) KR20240155291A (https=)
CN (1) CN118785906A (https=)
AU (1) AU2023229221A1 (https=)
CA (1) CA3248808A1 (https=)
IL (1) IL314494A (https=)
MX (1) MX2024010644A (https=)
WO (1) WO2023166487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656165A (zh) * 2023-09-20 2025-03-21 上海美悦生物科技发展有限公司 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
AU2023229221A1 (en) 2024-08-15
EP4486343A1 (en) 2025-01-08
IL314494A (en) 2024-09-01
JP2025507830A (ja) 2025-03-21
WO2023166487A1 (en) 2023-09-07
CA3248808A1 (en) 2023-09-07
US20250195492A1 (en) 2025-06-19
MX2024010644A (es) 2024-09-06
CN118785906A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
CN109152756B (zh) 胆汁淤积性疾病的治疗方法
EP3922246A1 (en) Cenicriviroc for the treatment of fibrosis
KR20240155291A (ko) 루푸스 신염 치료를 위한 입타코판의 용도
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
EP3185881B1 (en) Methods, agents and compositions for treatment of inflammatory conditions
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis
Löfberg et al. Oral budesonide in active Crohn's disease
US11331292B2 (en) Methods of treatment of cholestatic diseases
US12290498B2 (en) Methods of treatment of cholestatic diseases
CN105228453A (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
EP4355329A1 (en) Method of treating an autoimmune hematological disorder
KR20240004947A (ko) 비정형 용혈성 요독 증후군 치료용 입타코판
Meyrier Management of idiopathic nephrotic syndrome in adults: minimal change disease and focal segmental glomerulosclerosis
KR20250150635A (ko) 인자 b 억제제의 사용 방법
JPWO2006046528A1 (ja) 糸球体疾患治療剤
RU2754509C1 (ru) Способ лечения первичной мембранозной нефропатии с нефротическим синдромом и повышенным уровнем анти-plar2
Appel et al. New diagnostic tests and new therapies for glomerular diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000